Pernix holders agree to convert all $65 million 8% notes due 2019

By Marisa Wong

Madison, Wis., April 17 – Pernix Therapeutics Holdings, Inc. entered into an agreement on April 16 with all of the holders of its $65 million of 8% convertible senior notes due 2019 to convert the securities into stock.

The holders also agreed to the removal of substantially all of the restrictive covenants in the indenture governing the 8% convertibles, according to an 8-K filing with the Securities and Exchange Commission.

The holders will receive a total of 2,338,129 shares of common stock.

Pernix priced a new offering of $130 million of 4.25% convertible senior notes due 2021 after the close on Thursday.

As announced on April 13, Pernix is also currently seeking consents for proposed amendments to the indenture governing its 12% senior secured notes due 2020.

The amendments to the 12% notes would allow the company to incur additional debt to the extent it ratably reduces the outstanding amount of its 8% convertibles, provided that the additional debt does not exceed $42.2 million, according to a prior press release.

The specialty pharmaceutical company is based in Morristown, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.